CN114432423A - 用于治疗疾病和病症的NFkB活性的抑制剂 - Google Patents

用于治疗疾病和病症的NFkB活性的抑制剂 Download PDF

Info

Publication number
CN114432423A
CN114432423A CN202111512016.7A CN202111512016A CN114432423A CN 114432423 A CN114432423 A CN 114432423A CN 202111512016 A CN202111512016 A CN 202111512016A CN 114432423 A CN114432423 A CN 114432423A
Authority
CN
China
Prior art keywords
group
core sequence
seq
ala
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111512016.7A
Other languages
English (en)
Chinese (zh)
Inventor
拉金德拉·萨哈伊·巴特纳格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN114432423A publication Critical patent/CN114432423A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202111512016.7A 2014-09-26 2015-09-25 用于治疗疾病和病症的NFkB活性的抑制剂 Pending CN114432423A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
CN201580064157.3A CN106999535B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580064157.3A Division CN106999535B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂

Publications (1)

Publication Number Publication Date
CN114432423A true CN114432423A (zh) 2022-05-06

Family

ID=55582262

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111512016.7A Pending CN114432423A (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFkB活性的抑制剂
CN201580064157.3A Active CN106999535B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580064157.3A Active CN106999535B (zh) 2014-09-26 2015-09-25 用于治疗疾病和病症的NFκB活性的抑制剂

Country Status (7)

Country Link
US (5) US10030048B2 (https=)
EP (1) EP3197474B1 (https=)
JP (3) JP6851965B2 (https=)
CN (2) CN114432423A (https=)
AU (2) AU2015320341B2 (https=)
CA (1) CA2999711A1 (https=)
WO (1) WO2016049580A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CA3191058A1 (en) * 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
CN1233171A (zh) * 1996-09-05 1999-10-27 研究发展基金会 用咖啡酸苯乙酯(CAPE)、CAPE的衍生物、辣椒素(8－甲基－N－香兰基－6－壬烯酰胺)和树脂毒素来抑制核转录因子NF－κB
WO2002026935A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California TGF-β INHIBITORS AND METHODS
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
US20120064099A1 (en) * 2008-10-30 2012-03-15 The Trustees Of Columbia University In The City Of New York Compounds that inhibit nfkb and bace1 activity

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
WO1991002537A1 (en) 1989-08-14 1991-03-07 The Regents Of The University Of California Synthetic peptides that enhance cell binding
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
PT1678209E (pt) * 2003-10-07 2011-06-30 Yeda Res & Dev Anticorpos para a nik, a sua preparação e a sua utilização
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
WO2006133027A2 (en) 2005-06-03 2006-12-14 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
CA2722754A1 (en) 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
WO2011087768A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
CA3191058A1 (en) 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
CN1233171A (zh) * 1996-09-05 1999-10-27 研究发展基金会 用咖啡酸苯乙酯(CAPE)、CAPE的衍生物、辣椒素(8－甲基－N－香兰基－6－壬烯酰胺)和树脂毒素来抑制核转录因子NF－κB
WO2002026935A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California TGF-β INHIBITORS AND METHODS
US20030083265A1 (en) * 2000-09-29 2003-05-01 Bhatnagar Rajendra S. TGF-beta inhibitors and methods
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
US20120064099A1 (en) * 2008-10-30 2012-03-15 The Trustees Of Columbia University In The City Of New York Compounds that inhibit nfkb and bace1 activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. BESRAY UNAL ET AL.: "INHIBITOR PEPTIDE DESIGN FOR NF-κB: MARKOV MODEL & GENETIC ALGORITHM", 《5TH INTERNATIONAL SYMPOSIUM ON HEALTH INFORMATICS AND BIOINFORMATICS》, 20 April 2010 (2010-04-20), pages 1 - 9 *
K. KAVITHA ET AL.: "Cytomodulin-1, a synthetic peptide abrogates oncogenic signaling pathways to impede invasion and angiogenesis in the hamster cheek pouch carcinogenesis model", 《BIOCHIMIE》, vol. 102, 27 February 2014 (2014-02-27), pages 56 - 67, XP055474072, DOI: 10.1016/j.biochi.2014.02.010 *
刘磊 等: "霉酚酸酯对糖尿病大鼠肾组织中TGF-β1与OPN表达的影响", 《中华全科医学》, vol. 9, no. 5, 8 May 2011 (2011-05-08), pages 676 - 696 *
张劲松 等: "转录因子NF-κB的研究进展", 《科学通报》, vol. 47, no. 5, 15 March 2002 (2002-03-15), pages 323 - 329 *

Also Published As

Publication number Publication date
CA2999711A1 (en) 2016-03-31
JP2021091728A (ja) 2021-06-17
JP7184946B2 (ja) 2022-12-06
US20260015386A1 (en) 2026-01-15
JP6851965B2 (ja) 2021-03-31
US10030048B2 (en) 2018-07-24
EP3197474B1 (en) 2023-06-07
WO2016049580A2 (en) 2016-03-31
US11773135B2 (en) 2023-10-03
JP2018500274A (ja) 2018-01-11
US20240083941A1 (en) 2024-03-14
EP3197474A2 (en) 2017-08-02
EP3197474A4 (en) 2018-08-22
US12325760B2 (en) 2025-06-10
AU2021221579B2 (en) 2025-01-23
JP2023010979A (ja) 2023-01-20
US20170051012A1 (en) 2017-02-23
WO2016049580A3 (en) 2016-05-19
CN106999535B (zh) 2021-12-21
US11174286B2 (en) 2021-11-16
CN106999535A (zh) 2017-08-01
US20220106359A1 (en) 2022-04-07
AU2021221579A1 (en) 2021-09-16
US20180298055A1 (en) 2018-10-18
AU2015320341A1 (en) 2017-05-04
AU2015320341B2 (en) 2021-05-27
EP3197474C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US12325760B2 (en) Inhibitors of NF kappa-B activity for treatment of diseases and disorders
JP5824085B2 (ja) Ｊｎｋシグナル伝達経路に対する、細胞透過性のペプチド性阻害剤の種々の、疾病を治療するための使用
ES2777652T3 (es) Modulación de la actividad de proneurotrofinas
CA2628635C (en) Mu-conotoxin peptides and use thereof as a local anesthetic
BR112015001451B1 (pt) Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
ES2730050T3 (es) Interleuquina 38 truncada en el extremo terminal N
BR112017000591B1 (pt) Peptideomimético e composição compreendendo o mesmo
US20230391826A1 (en) Compositions and methods for treating diseases
CN114605497A (zh) 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
JP2010229093A (ja) 新規ＣｈｅｍｅｒｉｎＲアゴニスト
JP2020515294A (ja) アブラナ科のタンパク質抽出物およびその使用
CN102807609B (zh) 一种预防和/或治疗疼痛的多肽及其应用
HK40074479A (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
WO2014095977A1 (en) Novel pellino peptide
EP2670416B1 (en) A novel high affinity bivalent helically constrained peptide against cancer
US20170319650A1 (en) Maspin-based inhibition of osteoclast activity and promotion of bone formation
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
ITMI20081119A1 (it) Frammenti di muc16 ad attivita antigenica e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074479

Country of ref document: HK